AAPL   321.95 (+0.03%)
MSFT   183.34 (+0.28%)
FB   229.02 (-1.25%)
AMZN   2,467.45 (-0.15%)
NVDA   350.91 (-0.38%)
CGC   16.34 (-0.85%)
BABA   213.27 (+3.24%)
GE   7.03 (+3.99%)
TSLA   895.77 (-0.26%)
AMD   52.87 (-1.42%)
T   30.91 (-0.06%)
ACB   14.66 (+3.97%)
F   5.90 (+0.51%)
GILD   73.22 (-2.58%)
DIS   118.30 (-0.40%)
BAC   24.88 (+1.10%)
AAPL   321.95 (+0.03%)
MSFT   183.34 (+0.28%)
FB   229.02 (-1.25%)
AMZN   2,467.45 (-0.15%)
NVDA   350.91 (-0.38%)
CGC   16.34 (-0.85%)
BABA   213.27 (+3.24%)
GE   7.03 (+3.99%)
TSLA   895.77 (-0.26%)
AMD   52.87 (-1.42%)
T   30.91 (-0.06%)
ACB   14.66 (+3.97%)
F   5.90 (+0.51%)
GILD   73.22 (-2.58%)
DIS   118.30 (-0.40%)
BAC   24.88 (+1.10%)
AAPL   321.95 (+0.03%)
MSFT   183.34 (+0.28%)
FB   229.02 (-1.25%)
AMZN   2,467.45 (-0.15%)
NVDA   350.91 (-0.38%)
CGC   16.34 (-0.85%)
BABA   213.27 (+3.24%)
GE   7.03 (+3.99%)
TSLA   895.77 (-0.26%)
AMD   52.87 (-1.42%)
T   30.91 (-0.06%)
ACB   14.66 (+3.97%)
F   5.90 (+0.51%)
GILD   73.22 (-2.58%)
DIS   118.30 (-0.40%)
BAC   24.88 (+1.10%)
AAPL   321.95 (+0.03%)
MSFT   183.34 (+0.28%)
FB   229.02 (-1.25%)
AMZN   2,467.45 (-0.15%)
NVDA   350.91 (-0.38%)
CGC   16.34 (-0.85%)
BABA   213.27 (+3.24%)
GE   7.03 (+3.99%)
TSLA   895.77 (-0.26%)
AMD   52.87 (-1.42%)
T   30.91 (-0.06%)
ACB   14.66 (+3.97%)
F   5.90 (+0.51%)
GILD   73.22 (-2.58%)
DIS   118.30 (-0.40%)
BAC   24.88 (+1.10%)
Log in

NASDAQ:ADXSAdvaxis Stock Price, Forecast & News

$0.75
+0.04 (+5.61 %)
(As of 06/2/2020 02:04 PM ET)
Add
Compare
Today's Range
$0.70
Now: $0.75
$0.76
50-Day Range
$0.59
MA: $0.68
$0.79
52-Week Range
$0.21
Now: $0.75
$2.95
Volume910,449 shs
Average Volume1.13 million shs
Market Capitalization$45.37 million
P/E RatioN/A
Dividend YieldN/A
Beta3.55
Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Read More
Advaxis logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.88 million
Book Value$2.30 per share

Profitability

Net Income$-16,610,000.00
Net Margins-3,108.18%

Miscellaneous

Employees58
Market Cap$45.37 million
Next Earnings Date6/11/2020 (Confirmed)
OptionableOptionable

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

How has Advaxis' stock been impacted by COVID-19 (Coronavirus)?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ADXS stock has increased by 13.0% and is now trading at $0.7531. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Advaxis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Advaxis.

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Thursday, June 11th 2020. View our earnings forecast for Advaxis.

How can I listen to Advaxis' earnings call?

Advaxis will be holding an earnings conference call on Thursday, June 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) announced its earnings results on Friday, March, 13th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.04. Advaxis had a negative return on equity of 82.13% and a negative net margin of 3,108.18%. View Advaxis' earnings history.

Has Advaxis been receiving favorable news coverage?

News headlines about ADXS stock have been trending very positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of 3.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAdvaxis.

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

Who are Advaxis' key executives?

Advaxis' management team includes the following people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Who are Advaxis' major shareholders?

Advaxis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.41%) and Private Advisor Group LLC (0.33%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel. View institutional ownership trends for Advaxis.

Which institutional investors are buying Advaxis stock?

ADXS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.75.

How big of a company is Advaxis?

Advaxis has a market capitalization of $45.37 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is www.advaxis.com.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.